GlaxoSmithKline's ViiV Healthcare Finds Positive Data In HIV Drug Study
July 22 2019 - 12:52PM
Dow Jones News
By Adriano Marchese
GlaxoSmithKline PLC (GSK.LN) said Monday that has found positive
data over a 96-week period from phase 3 study of investigational
Fostemsavir in patients with HIV.
ViiV Healthcare, of which GlaxoSmithKline is a majority
shareholder, said rates of virologic suppression and immunologic
response increased from week 48 to week 96 in a difficult-to-treat
population with multi-drug resistant HIV-1.
The study found that at week 96, 60% of patients receiving
Fostemsavir as well as optimized background treatments in the
randomized cohort achieved virologic suppression--an increase of 6%
from week 48 results.
ViiV plans to begin the submission of regulatory applications
for Fostemsavir with the U.S. new-drug application later this
year.
Write to Adriano Marchese at adriano.marchese@dowjones.com
(END) Dow Jones Newswires
July 22, 2019 12:37 ET (16:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024